Please ensure Javascript is enabled for purposes of website accessibility

What's Causing Catalent's Stock to Crash 13.6% Today

By Todd Campbell - May 5, 2016 at 4:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A shutdown at a facility in France and shifts in product mix led to lackluster earnings last quarter.

What: After Catalent (CTLT 1.07%) reported fiscal third-quarter earnings results that were shy of industry watchers' forecasts, its shares were trading down 13.6% at 3:45 p.m. ET today. 

So what: Catalent is a global provider of solutions used to create and develop medicines and its technologies are widely used by drugmakers producing both small-molecule and biologic drugs.

In the fiscal third quarter, Catalent's revenue increased 2% in constant currency, to $438 million, but fell 2% when adjusted for currency exchange headwinds. The bottom line, however, is the cause of today's drop in share price. In the quarter, Catalent reports that an unfavorable shift in product mix and the temporary suspension of activities at its Beinheim, France, facility resulted in adjusted net income of $0.20 per share. That was $0.11 below what investors were looking for and far lower than the $0.40 earned in the same quarter a year ago.

Management also reported that SG&A expenses increased to 21.3% of revenue in the quarter, compared to 18.1% of revenue in the third quarter last year. Also, third-quarter gross margin dropped 5.3% to 28.8% versus a year ago. 

Now what: It wasn't all bad for the company. Sales within its development and clinical services segment grew 9% to $112.6 million in the quarter, and revenue from the company's medication delivery solutions segment was $68.3 million, an increase of 12% from a year ago. The big drag was the oral technologies group, whose sales fell 8% to $260.8 million.

Assuming that the restart of activity at Beinheim goes smoothly, it's possible that this dip in profit will be temporary. But even so, I'm not interested in stepping up and buying shares on this decline. Shares aren't overly pricey in terms of P/E, but the company is sitting on $1.9 billion in debt and just $134 million in cash, so until I'm sure that its profit drop is a one-off event, I'm not willing be a buyer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Catalent, Inc. Stock Quote
Catalent, Inc.
$107.29 (1.07%) $1.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.